Novo Nordisk secures EU nod for higher Wegovy dose amid intensifying GLP-1 competition
EU approves 7.2 mg Wegovy for obesity. Explore what this means for efficacy, competition and reimbursement across Europe.
Pharma & Biotech
Pharma & Biotech
Biofrontera targets U.S. label expansion for Ameluz in trunk and extremities
Phase 1 PK data bring Ameluz closer to broader FDA review. Explore the regulatory stakes and market impact in actinic keratosis.
Pharma & Biotech
Can Dialed Moods make biohacking sustainable beyond niche wellness communities
Dialed Moods expands its biohacking strategy with plant-based supplements. Explore what this shift means for the future of consumer wellness.
Pharma & Biotech
Why Newron’s EUR 38m financing matters for Phase III evenamide development in treatment-resistant schizophrenia
Newron Pharmaceuticals secures up to EUR 38 million to advance evenamide Phase III trials. Find out what this means for treatment-resistant schizophrenia.
Pharma & Biotech
Why Compass Pathways’ upcoming COMP360 data could redefine late-stage psychedelic drug development
Compass Pathways is set to release pivotal Phase 3 COMP360 data in treatment-resistant depression. Find out why this readout could reshape psychedelic drug development.
Medical Devices & Diagnostics
Delphi Diagnostics data challenges one-size-fits-all use of extended endocrine therapy in breast cancer
SABCS data suggests endocrine activity may predict who truly benefits from extended endocrine therapy. Here is what Delphi Diagnostics’ findings mean.
Pharma & Biotech
Can subcutaneous infliximab change how clinicians manage drug holidays in Crohn’s disease and ulcerative colitis
New ECCO 2026 data explore whether subcutaneous infliximab can reliably recapture disease control after treatment interruption. Read the analysis.
Pharma & Biotech
Genentech advances Gazyva toward first approval in primary membranous nephropathy after Phase III win
Discover how Genentech’s Gazyva Phase III data could reshape treatment goals in membranous nephropathy and what regulators and clinicians will watch next.
Pharma & Biotech
Why Lilly’s LIBRETTO-432 results matter beyond selpercatinib’s event-free survival win
Eli Lilly and Company (Lilly) announced that its selective RET inhibitor selpercatinib, marketed as Retevmo, achieved a highly statistically significant improvement in investigator-assessed event-free survival when used as adjuvant therapy in patients with stage II–IIIA RET fusion-positive non-small cell lung cancer, based on topline results from the Phase 3 LIBRETTO-432 trial. The study compared selpercatinib
Pharma & Biotech
DifGen Pharmaceuticals expands complex generics footprint with fluorometholone ophthalmic suspension approval
DifGen Pharmaceuticals secures rare FDA approval for fluorometholone ophthalmic suspension. Find out why this complex generic matters for ophthalmology markets.